tirzepatide cardiovascular outcome Real-World Outcomes of Obesity Treatment With Versus Semaglutide in Non-Diabetic Adults In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF tirzepatide cardiovascular outcomes trial results

a review

Always so friendly and welcoming that you never feel uncomfortable about talking about your weight problems to them

Long-term use of tirzepatide may extend anti-inflammatory benefits by maintaining reduced body weight, improving insulin sensitivity, and supporting sustained metabolic health

Season with salt and pepper to your liking

Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement